Nuvalent Inc (NUVL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvalent Inc (NUVL) has a cash flow conversion efficiency ratio of -0.079x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.40 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NUVL net asset quality index to measure how much of total assets are equity-financed.
Nuvalent Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Nuvalent Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Nuvalent Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Nuvalent Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvalent Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CITIC Securities Company Limited
F:CI9
|
0.221x |
|
ALSTOM S.A. UNSP.ADR 1/10
F:AOMU
|
N/A |
|
HudBay Minerals Inc
TO:HBM
|
0.052x |
|
Charles River Laboratories
NYSE:CRL
|
0.014x |
|
Indra A
MC:IDR
|
0.004x |
|
China Steel Corp
TW:2002
|
0.028x |
|
Vietnam JSCmmercial Bank for Industry and Trade
VN:CTG
|
-0.013x |
|
Hella KGaA Hueck & Co
XETRA:HLE
|
0.175x |
Annual Cash Flow Conversion Efficiency for Nuvalent Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Nuvalent Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Nuvalent Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.25 Billion | $-275.21 Million | -0.220x | -27.44% |
| 2024-12-31 | $1.07 Billion | $-185.06 Million | -0.173x | -21.51% |
| 2023-12-31 | $700.56 Million | $-99.74 Million | -0.142x | -1.45% |
| 2022-12-31 | $462.98 Million | $-64.97 Million | -0.140x | 0.00% |
| 2021-12-31 | $285.04 Million | $-40.00 Million | -0.140x | -129.40% |
| 2020-12-31 | $-31.32 Million | $-14.95 Million | 0.477x | -14.56% |
| 2019-12-31 | $-17.26 Million | $-9.64 Million | 0.559x | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more